MARKET

CHRS

CHRS

Coherus Bioscien
NASDAQ
1.610
+0.110
+7.33%
After Hours: 1.590 -0.02 -1.23% 16:35 12/13 EST
OPEN
1.500
PREV CLOSE
1.500
HIGH
1.650
LOW
1.500
VOLUME
2.54M
TURNOVER
--
52 WEEK HIGH
3.700
52 WEEK LOW
0.6603
MARKET CAP
185.49M
P/E (TTM)
-18.0493
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at CHRS last week (1202-1206)?
Weekly Report · 4d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 12/06 16:20
Coherus Biosciences (CHRS) Receives a Buy from Truist Financial
TipRanks · 12/05 16:57
TD Cowen Reaffirms Their Buy Rating on Coherus Biosciences (CHRS)
TipRanks · 12/05 16:53
Coherus BioSciences Is Maintained at Outperform by Baird
Dow Jones · 12/05 13:23
Baird Maintains Outperform on Coherus BioSciences, Raises Price Target to $6
Benzinga · 12/05 13:13
Coherus Biosciences price target raised to $6 from $4 at Baird
TipRanks · 12/05 12:02
Coherus Biosciences Announces Board Member Resignation
TipRanks · 12/04 21:50
More
About CHRS
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. The Company’s immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an IL-27 antagonistic antibody, which is being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is a highly selective, cytolytic anti-CCR8 antibody, which is in a Phase I study in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via the pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor, and UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta.

Webull offers Coherus Biosciences Inc stock information, including NASDAQ: CHRS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CHRS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CHRS stock methods without spending real money on the virtual paper trading platform.